ADMA Biologics (ADMA) Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Is ACAD or ADMA more profitable?

ADMA Biologics has a net margin of 45.01% compared to ACADIA Pharmaceuticals' net margin of 22.97%. ADMA Biologics' return on equity of 47.16% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	22.97%	17.46%	10.75%
ADMA Biologics	45.01%	47.16%	30.51%

Do analysts prefer ACAD or ADMA?

ACADIA Pharmaceuticals presently has a consensus price target of $27.88, suggesting a potential upside of 32.86%. ADMA Biologics has a consensus price target of $27.67, suggesting a potential upside of 49.47%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Do insiders & institutionals have more ownership in ACAD or ADMA?

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 26.5% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the media refer more to ACAD or ADMA?

In the previous week, ACADIA Pharmaceuticals had 4 more articles in the media than ADMA Biologics. MarketBeat recorded 8 mentions for ACADIA Pharmaceuticals and 4 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.54 beat ACADIA Pharmaceuticals' score of 1.41 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has stronger earnings & valuation, ACAD or ADMA?

ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$957.80M	3.67	$226.45M	$1.37	15.31
ADMA Biologics	$426.45M	10.36	$197.67M	$0.85	21.78

Which has more volatility & risk, ACAD or ADMA?

ACADIA Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Summary

ACADIA Pharmaceuticals and ADMA Biologics tied by winning 8 of the 16 factors compared between the two stocks.